company background image
CUE

Cue Biopharma NasdaqCM:CUE Stock Report

Last Price

US$3.24

Market Cap

US$114.6m

7D

35.6%

1Y

-75.0%

Updated

05 Oct, 2022

Data

Company Financials +
CUE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CUE Stock Overview

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders.

Cue Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cue Biopharma
Historical stock prices
Current Share PriceUS$3.24
52 Week HighUS$18.42
52 Week LowUS$2.18
Beta1.66
1 Month Change4.85%
3 Month Change13.29%
1 Year Change-75.02%
3 Year Change-57.98%
5 Year Changen/a
Change since IPO-72.14%

Recent News & Updates

Oct 04

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Cue Biopharma (NASDAQ:CUE) on Tuesday said it had got a fast track designation from the U.S. FDA for its drug candidate CUE-101 for the treatment of head and neck cancer associated with human papilloma virus. CUE stock jumped 9.6% to $2.62 in early trading. The designation was for CUE-101 as a monotherapy and in combination with Merck's (MRK) Keytruda for the treatment of human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. "To date in its Phase 1b clinical trials, CUE-101 has demonstrated a favorable tolerability profile and single-agent anti-tumor activity in monotherapy as well as encouraging anti-tumor clinical activity in combination with (Keytruda)," CUE senior vice president of clinical development Matteo Levisetti said in a statement.

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

The analysts covering Cue Biopharma, Inc. ( NASDAQ:CUE ) delivered a dose of negativity to shareholders today, by...

Shareholder Returns

CUEUS BiotechsUS Market
7D35.6%1.2%1.9%
1Y-75.0%-19.3%-18.8%

Return vs Industry: CUE underperformed the US Biotechs industry which returned -20.8% over the past year.

Return vs Market: CUE underperformed the US Market which returned -18.2% over the past year.

Price Volatility

Is CUE's price volatile compared to industry and market?
CUE volatility
CUE Average Weekly Movement13.4%
Biotechs Industry Average Movement11.2%
Market Average Movement7.0%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: CUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CUE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201458Dan Passerihttps://www.cuebiopharma.com

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases.

Cue Biopharma, Inc. Fundamentals Summary

How do Cue Biopharma's earnings and revenue compare to its market cap?
CUE fundamental statistics
Market CapUS$114.64m
Earnings (TTM)-US$48.84m
Revenue (TTM)US$11.68m

9.8x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CUE income statement (TTM)
RevenueUS$11.68m
Cost of RevenueUS$42.44m
Gross Profit-US$30.77m
Other ExpensesUS$18.07m
Earnings-US$48.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.38
Gross Margin-263.51%
Net Profit Margin-418.28%
Debt/Equity Ratio16.6%

How did CUE perform over the long term?

See historical performance and comparison